Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ETON
BuyPremium GrowerEton Pharmaceuticals, Inc. · Healthcare · United States · $1.7B · Avg Vol: $37M/d
COMPANY DESCRIPTION
Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative products for rare diseases and other high-unmet-need indications. The company primarily utilizes the 505(b)(2) regulatory pathway to efficiently bring differentiated drug formulations to market, often addressing pediatric or critical care settings. It operates as a nimble pharmaceutical firm, strategically targeting niche markets with its portfolio of neurology, cardiology, and rare disease products.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|
| Revenue | 21.3M | 31.6M | 39.0M | 80.0M | 55.5% | 105.6M | 149.7M | 87.2% |
| EPS | -0.36 | -0.04 | -0.15 | -0.17 | — | 0.39 | — | — |
| Shares | 25.4M | 25.7M | 26.7M | 27.0M | +6.7% | 28.6M | — | — |
| Debt | 6.5M | 5.4M | 29.9M | 31.0M | 68.2% | 29.2M | — | — |
| Equity | 13.1M | 15.5M | 24.4M | 26.2M | 26.0% | — | — | — |
| Op CF | 4.8M | 6.8M | 1.0M | 10.5M | 29.7% | 15.1M | — | — |
| Inv CF | -2.8M | -0.8M | -40.0M | -0.3M | — | — | — | — |
| Fin CF | -0.1M | -1.0M | 32.6M | 0.8M | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ETON are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ETON | Eton Pharmaceuticals, Inc.(you) | $1.7B | 72 | Buy |
| PAHC | Phibro Animal Health Corporation | $1.5B | 74 | Buy |
| PBH | Prestige Consumer Healthcare Inc. | $2.5B | 67 | Buy |
| XERS | Xeris Biopharma Holdings, Inc. | $1.5B | 60 | Hold |
| COLL | Collegium Pharmaceutical, Inc. | $786M | 72 | Buy |
| ANIP | ANI Pharmaceuticals, Inc. | $1.7B | 92 | Strong Buy |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.5B | 85 | Strong Buy |
| PCRX | Pacira BioSciences, Inc. | $1.0B | 85 | Strong Buy |
| GTII.CN | Green Thumb Industries Inc. | $1.6B | 94 | Strong Buy |
| TRLV | Trulieve Cannabis Corp. | $2.3B | 90 | Strong Buy |
Peer medians: ROE -30.8% · P/E 26.9x · Gross margin 58.1%